Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site discomfort, Injection site erythema, Injection site induration, Injection site pruritus, Injection site swelling
Clinical narrative: Redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection; Redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection; Redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection; Redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection; Redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection; Quickly spread to a welt 4inches by 3 inches and growing; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13Jun2022 at 15:45 as dose 3 (booster), single (Lot number: FN2908) at the age of 61 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Breast cancer" (unspecified if ongoing); "Known allergies: Unknown food allergy" (unspecified if ongoing), notes: Known allergies: Unknown food allergy. Concomitant medication(s) included: ANASTROZOLE. Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: ER8731, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 15Apr2021, when the patient was 60-year-old, for COVID-19 Immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: ER2613, Vaccine Administration Time: 01:45 PM), administration date: 23Mar2021, when the patient was 60-year-old, for COVID-19 Immunization. The following information was reported: URTICARIA (non-serious) with onset 14Jun2022 at 08:00, outcome "recovering", described as "Quickly spread to a welt 4inches by 3 inches and growing"; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE WARMTH (non-serious), VACCINATION SITE PRURITUS (non-serious), VACCINATION SITE DISCOMFORT (non-serious) all with onset 14Jun2022 at 08:00, outcome "recovering" and all described as "Redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection". The events "redness, swelling, warmth, hardness, itchiness and discomfort around the site of injection" and "quickly spread to a welt 4inches by 3 inches and growing" required physician office visit. Therapeutic measures were taken as a result of vaccination site swelling, vaccination site erythema, vaccination site warmth, vaccination site pruritus, vaccination site discomfort, urticaria.  Additional information: Serious: No  Seriousness criteria-Results in death: No Seriousness criteria-Life threatening: No Seriousness criteria-Caused/prolonged hospitalization: No Seriousness criteria-Disabling/Incapacitating: No Seriousness criteria-Congenital anomaly/birth defect: No. If other vaccine in four weeks: No. Other medication in 2 weeks: Centrum Silver Multivitamin for Adults 50 Plus. Ae treatment: Cold compresses, Stronger antihistamines. If COVID prior vaccination: No. If COVID tested post vaccination: No